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INTRODUCTION 
This Reply Brief is submitted in response to the Brief of 
the Respondent filed with this Court on August 30, 1982. 1 Both 
parties have provided Statements of Fact to this Court. E.R. 
Squibb & Sons, Inc. ( 11 Squibb 11 ) believes that certain "facts 11 
related by counsel for the Barsons require correction. However, 
rather than engaging in a point-by-point debate, we will address 
these matters at various points throughout this Reply Brief. 
1 
References to the Briefs and record in this case will be made 
in the following manner: 
(1) The Brief of Appellant E.R. Squibb & Sons, Inc. filed 
on June 30, 1982, will be referred to as "Squibb Brief." 
(2) The Brief of the Respondent Elizabeth Ann Barson filed 
on August 30, 1982, will be referred to as "Barson Brief." 
(3) The Reply Brief of Appellant E.R. Squibb & Sons, Inc. 
will be referred to as "Reply Brief." 
(4) One volume of separately numbered papers and pleadings 
filed in the trial court and designated for inclusion in the 
record on appeal will be prefaced by the letter "R." 
(5) A separate one-volume transcript of the proceedings at 
pretrial will be prefaced by the letters "PR.If 
(6) Sixteen volumes of transcript of trial and post-trial 
proceedings will be referred to by the abbreviation "Tr." 
(7) ·All exhibits received at trial will be referred to by 
the Letters "P .Ex." for plaintiffs' Exhibits and 110.Ex." for 
Squibb's Exhibits. 
(8) The Minutes, November 5-6, 1981 Meeting, "Fertility and 
Maternal Health Drugs Advisory Committee," Food and Drug Adminis-
tration admitted as a result of a motion to supplement the record 
are included as Appendix A. 
(9) Proposed Instruction lOA submitted to the trial court 
by Squibb is included as Appendix B. 
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The appellant and respondent apparently agree that the 
critical question presented in the trial court was: whether in 
medical probability Elizabeth Ann Barson' s birth defects were 
caused by the administration of Delalutin to her mother? This 
pivotal question was resolved in the Barsons' favor by the jury 
after several categories of improperly admitted and highly prejudi-
cial evidence were considered by it. 
Squibb does not ask that this Court substitute its views on 
the evidence for that of the jury. Rather, each of the evidentiary 
errors related in Squibb's initial Brief were so sigilificant that 
the jury's verdict must be presumed to have been affected. 
Cerritos Trucking Co. v. Utah Venture No. 1, 645 P.2d 608 (Utah 
1982); Lee v. Mitchell Funeral Home Ambulance~., 606 P.2d 259 
(Utah 1980) (reversal based on evidential errors appropriate if 
there is a reasonable likelihood that in absence of error there 
would be a result more favorable to the complaining party). It 
is on this basis that the jury's verdict must be set aside and a 
new trial directed. U.R.C.P. 61; U.R.E. 4(b). 
Squibb also has complained that the jury's verdict in this 
case must be reversed because it was improperly instructed about 
the doctrine of strict liability as applied in a prescription 
drug case and that the trial court erred as a matter of law when 
it declined to dismiss the claim that Squibb negligently failed 
to test Delalutin in animals to determine its teratogenic potential. 
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As will be seen in this Reply Brief, the respondent does not 
affirmatively challenge these arguments. Rather, she now suggests 
alternative bases and legal theories for the jury's verdict and 
argues that the challenged evidence is admissible on a variety of 
alternate grounds not suggested during the trial. For the reasons 
presented here, and in its initial Brief, Squibb believes these 
arguments to be insubstantial. The judgment below must be reversed 
and the appellant granted a new trial. 
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ARGUMENT 
POINT I 
THE RESPONDENT FAILS TO PROVIDE THIS 
COURT WITH ANY BASIS FOR ADMITTING THE FDA- , 
MANDATED PACKAGE INSERTS. 
A. The FDA-Mandated Physician and Patient 
Package Inserts are Inadmissible Hearsay. 
The parties both at the trial level and in this Court recog-
nize that a pivotal evidential issue decided adversely to Squibb 
was the propriety of admitting in evidence subsequently mandated 
physician and patient package warnings. A review of the trial 
record discloses that these warnings were not admitted for limited 
purposes such as feasibility, impeachment or rebuttal now urged 
by the respondent. Compare Barson Brief at 28-34 with PR 45-50, 
68-72; Trll93-1197, 1495-1496. Rather, the trial court admitted 
them in support of the respondent's contention that Delalutin was 
both an ineffective drug and that its administration could lead 
to an incalculable increased risk of birth defects including limb 
anomalies. These judgmental expressions by the FDA were hearsay 
and inadmissible except as provided in U. R. E. 63. The trial 
I judge never resolved the hearsay objections made by counsel for 
Squibb. See Squibb Brief at 26 n. 18. 2 
2 
The trial judge determined that these FDA-mandated warnings 
were not admissions of Squibb. The judge during argument observed 
"this I don't think could come in as an admission" (PR. -so). 
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The respondent has completely ignored this critical appel-
late issue in its Brief, arguing instead that the FDA-mandated 
warnings are a form of subsequent remedial conduct which should 
be admissible in evidence based upon both legal and policy grounds. 
The respondent ignores the fact, however, that U.R.E. 51 is a 
rule of exclusion. It. provides for the exclusion of otherwise 
admissible evidence on legal and policy grounds, not for the 
introduction of otherwise inadmissible evidence. 
The FDA warnings from the time of their introduction occupied 
a dominant place in this trial. Squibb Brief at 14-16. Although 
they were clearly used by the plaintiff to convince the jury that 
a cause and effect relationship existed between the administration 
of Delalutin and birth defects, the FDA, which had mandated these 
warnings, eschewed such a purpose. Rather, the Commissioner of 
Food and Drugs, at the time these warnings were mandated, noted 
that "it is not possible to draw ~ cause and effect relationship 
with progesterone or hydroxxprogesterone [Delalutin] based on 
these data." 43 Fed., Reg. 47178 (October 13, 1978) (emphasis 
added). 
The FDA, moreover, had a fundamentally different role to 
play than the jury in this case. In its role as this nation's 
public health guardian, the FDA might choose to act on the basis 
of incomplete information to protect the public from possible 
dangers. One necessarily expects that such a public agency, 
given its mandate, might act upon incomplete and preliminary 
information which may eventually turn out to be erroneous. 
-s-
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Because none of the circumstances surrounding publication of 
these warnings could be properly elicited on cross-examination, 
the jury was unfairly left with the impression that this nation's 
public health expert had made a judgment that Delalutin was in 
fact a teratogen--something which the FDA itself specifically 
disclaimed. 43 Fed Reg. 47178 (October 13, 1978). 3 
Courts have recognized that an agency's public responsi-
bilities and its actions in implementing them may affect the 
reliability of judgmental information contained in its pronounce-
ments. For example, in Zenith Radio .£2.!l?.. v. Matsushita Elec. 
3 
The appellant believes that it brought to the trial court's 
attention evidence which was not available during trial which was 
of such significance that had it been available at trial there is 
a reasonable likelihood that a different result would have occurred. 
That evidence was in the form of a recommendation by the FDA 
Fertility and Maternal Drugs Advisory Committee that Delalutin's 
labeling be changed to delete the warnings introduced at trial. 
Appendix A at 16-17. While we do not intend to reargue this 
issue, several statments by the respondent require correction. 
Inexplicably, the respondent advised this Court that "of signifi-
cance is ... [that] ... specific notice of the hearing was not 
published among the members of the medical and scientific coriiiiluility 
who take a position on the safety of the drug contrary to Squibb's." 
Barson Brief at 46 (emphasis added). This statement is erroneous. 
As with all meetings of the Fertility and Maternal Health Drugs 
Advisory Committee a formal notice of the meeting and subjects 
open for discussion were published in the Federal Register. 
Moreover, the notice provided instructions regarding reimbursement 
for those who wished to attend and present testimony. See 46 
Fed. Reg. 51033-51034 (October 15, 1981). ~ 
The respondent has quoted at length from the testimony of 
Dr. Eve Bargmann, a physician representing Public Citizen Health 
Research Group. What is significant is that following Dr. Bargmann's 
testimony the Committee continued to recommend that the FDA 
modify Delalutin's labeling by removing the warnings introduced 
in evidence in this case. It is this recommendation which, if 
hearsay is to be admitted in the form of mandated package inserts, 
is relevant and was available to meet the conclusions which the 
respondent sought to draw from them--that Delalutin caused birth 
defects. 
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Ind. Co., SOS F. Supp. 112S, 1147-llSO (E.D. Pa. 1980), a Federal 
District Court found that an agency's regulatory posture may cause 
potential problems affecting the reliability of its findings. In 
declining to receive a detailed report made by the Department of 
Commerce as evidence in a major antitrust case, the Zenith Court 
explained this phenomenon: 
[T]he extent to which ... findings are a 
function of an executive, administrative or 
legislative policy judgment or represent an 
implementation of policy ... [presents] oo• a 
variation on the theme of "motivational 
problems" identified as one of the Advisory 
Committee's trustworthiness criteria ... o In 
our view, where there exists within an agency 
a preconceived notion of the policy that the 
agency is attempting to implement o • • the 
11 findings" of that agency are to at least 
some degree a function of that preconceived 
notion, and though they may be "trustworthy" 
in light of the particular policy objectives 
the agency is attempting to further, they may 
or may not be trustworthy for other purposes. 
overriding policy concerns bring into question 
the objectivity of an agency's finding .... 
Zenith Radio £2.!:E,. v. Matsushita Elec. Ind. Co., 505 F. Supp. at 
1148-1149. 4 
In sum, the respondent has failed to provide a basis for the 
admissibility of this unreliable hearsay information at the trial 
level or here. Any legal or policy arguments made to this 
4 
The judgments reflected in the FDA mandated physician and 
patient package inserts were also based upon information which 
itself is in the process of evolution. As reflected in the 
recent recommendation of the FDA Committee responsible for evaluat-
ing the safety and efficacy of drugs used in pregnancy, information 
developed since the warnings were implemented has led that Commit-
tee to suggest that Delalutin's labeling be changed to omit these 
warnings. The FDA currently has this Committee's recommendation 
under advisement. Appendix A at 16-17. 
-7-Sponsored by the S.J. Quinney Law Library. Funding for digitization provided by the Institute of Museum and Library Services Library Services and Technology Act, administered by the Utah State Library. 
 Machine-generated OCR, may contain errors.
Court respecting the admission of subsequent remedial measures in 
strict liability cases cannot operate to permit the receipt of 
otherwise inadmissible evidence. 
B. The Post-1972 Physician and Patient Package 
Inserts Are Neither Relevant on the Issue of 
Causation Nor Should They Be Admitted on 
Public Policy Grounds. 
The respondent asks that this Court decline to follow U.R.E. 51 
in strict liability cases. U.R.E. 51 which excludes evidence of 
subsequent remedial conduct is based upon two concerns. First, 
the evidence is of questionable relevance since subsequent actions 
are not necessarily consistent with prior knowledge and/or culpable 
conduct. Second, permitting the introduction of evidence of 
remedial measures is likely to discourage them, particularly in 
close cases. This Court has agreed with both concerns in its 
previous decisions. The respondent, however, suggests that these 
policies have less value in a strict liability context. Most 
courts, however, which have considered the matter disagree. 5 
5 
As noted in our initial brief, the rule in Ault v. Int'l 
Harvester, !!!£., 528 P.2d 1148 (Cal. 1974), appears to be the 
minority one. It apparently has been adopted by the United 
States Court of Appeals for the Eighth Circuit and the courts of 
New York and South Dakota. Since our initial brief was filed the 
Supreme Court of Wyoming has suggested in dicta that the Ault 
rule should be adopted in Wyoming. See "Caldwell v. YamahaMO'tOr 
Co. Ltd. of Japan, 648 P.2d 519 (Wy0:---1982). As noted in our 
initial brief, the United States Courts of Appeals for the First, 
second, Third, Fourth, Sixth and Seventh Circuits have determined 
that subsequent remedial conduct is not admissible in strict 
liability actions. See Squibb Brief at 41-42. In addition, 
courts in the States of Indiana, Michigan, New Jersey, Ohio, 
Texas, Washington and Wisconsin have excluded evidence of subse-
quent warnings in strict liability cases. Since the filing of 
Squibb's initial brief an Appellate court in Arizona has also 
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Prior to the enactment of U.R.E. 51, this Court determined 
that subsequent remedial conduct is not admissible because it 
"does not establish or tend to establish knowledge .... Rather, 
it seems to negative such knowledge and well may have evidenced a 
desire to prevent [injuries] . " Bennett v. Pilot Products 
Co., 235 P.2d 525, 527 (Utah 1951). In a strict liability prescrip-
tion drug case involving a failure to warn, knowledge, of course, 
is a vital issue. Thus, the relevance concerns expressed over 30 
years ago by the Bennett court have the same vitality today. See 
also, ~., Ortho Pharmaceutical Corp. v. Chapman, 388 N.E.2d 
541, 561-562 (Ind. App. 1979). 
The question of relevance of these warnings to the issue of 
causation is particularly important in this case where the author 
of the warnings, the FDA, denies that they report a cause and effect 
relationship between Delalutin and teratogenic effects. Since at 
least one significant purpose served by the provisions of U.R.E. 51 
is to prevent the receipt of irrelevant evidence, excluding these 
FDA warnings is appropriate. 
The second policy reason supporting the exclusionary rule 
reflected in U.R.E. 51 is the recognition that people are loath 
to take actions which increase the risks of losing a lawsuit. The 
exclusion of subsequent remedial conduct is based on a societal 
5 (Cont'd) 
found that the policies expressed in its rule excluding subsequent 
remedial conduct were applicable in a products liability case 
involving strict liability. See Hallmark v. Allied Products 
£2!:p_., 646 P.2d 319 (Arizo Ap~1982) (the Arizona rule is the 
same as Fed. R. Evid. 407). 
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judgment that excluding such evidence will encourage prompt remed-
ial conduct especially in equivocal situations. See, ~. , 
Potter v. Dr. W.H. Groves Latter-Day Saints Hospital, 103 P.2d 
280, 282 (Utah 1940). ~also, Werner v. Upjohn Co., Inc., 628 
F. 2d 848, 857-858 · (4th Cir. 1980), cert. denied 449 U.S. 1080 
( 1981) . The responent has suggested that U. R. E. 51 does not 
require exclusion of evidence of subsequent remedial actions in 
a strict liability action. Although adoption of comments h, j 
and k to the Restatement of Torts (2d) § 402A by this Court will 
obviate such an argument, this Court should not get the misimpres-
sion that the policies expressed in U.R.E. 51 are inapplicable 
where strict liability is involved. 6 
The respondent suggests that by its terms U.R.E. 51 is inappli-
cable because evidence of subsequent measure is only rendered 
inadmissible to prove "negligence" or 11 culpable conducto" This 
Court has already answered this argument in a different context 
when it found that semantic difficulties in comparing strict 
liability and negligence should not obscure th~ policy objectives 
expressed in the law. Mulherin v. Ingersoll-Rand Co., 628 P.2d 
1301, 1304 (Utah 1981). It would seem then that if similar 
policies are reflected in excluding subsequent remedial conduct 
both in a negligence and strict liability matter, the exclusionary 
rule should be applied. 
6 
In. the Squibb Brief at 36-37 it is suggested that the Restate-
ment of Torts (2d) § 402A comments h, j and k provide that Squibb's 
duty to warn in a drug case should be measured by traditional 
concepts of negligence. Therefore, by its terms U.R.E. 51 is 
applicable to this case. 
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Using this rationale the vast majority of courts which have 
considered this issue have applied the exclusionary rule in a 
strict liability context. This approach was explained by the 
Second Circuit in Cann v. Ford Motor Co., 658 F.2d 54, 60 (2d 
Cir. 1981), cert. denied, U.S. , 102 s.ct. 2036 (1982), 
in the following way: 
Appellants point out that a negligence action 
places in issue whether the defendant's 
conduct was reasonable while a strict liability 
action involves whether the product was defec-
tive; they note that the jury focuses on the 
defendant in the negligence action, but solely 
upon the product in a strict liability action. 
However, the defendant must pay the judgment 
in both situations, regardless of where the 
jury's attention focused when they found against 
him. Since the policy considerations underlying-
[the rule excluding remedial conduct]-not to 
discourage persons from taking remedial measures 
is relevant to defendants sued under either 
theory, we do not see the significance of the 
distinction. A potential defendant must be 
equally concerned regardless of the theoretical 
rubric under which this highly prejudicial ... 
and extremely damaging evidence oo• is admitted. 
[Id. at 60; citations omitted; emphasis in the 
original] 
The respondent suggests that the public policy behind U.R.E. 51, 
however, should be suspended when the subsequent remedial conduct is 
7 in the form of warnings mandated by a governmental agency. This 
argument is not supported by the cases cited by the respondent. 
7 
This position is actually supportive of Squibb's argument 
that the warnings themselves are inadmissible hearsay. Certainly 
it is difficult to contend that where warnings are mandated by a 
governmental authority under law that compliance with that mandate 
constitutes an admission. See ~· Lindsay v. Ortho Pharmaceutical 
.£.Q.fE.., 637 F.2d 87, 94 (2d Cir. 1980); Squibb Brief at 30-32. 
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Instead, Werner v. Upjohn Co., Inc., 628 F.2d at 848, is dispositive. 
In that case the Fourth Circuit explained that in areas involving 
drug regulation the FDA relies upon full participation by the 
various drug companies and encourages voluntary action in advance 
of regulation. 8 These policies would be frustrated were the 
9 
exclusionary rule to be held inapplicable in drug related cases. 
8 
The respondent seeks to distinguish Werner suggesting that 
the drug in that case was a "new" drug while Delalutin was a drug 
which had been marketed for many years and was not a "new" drug. 
The respondent misunderstands the term "new drug." 21 U.S. c. 
§ 321 (p) defines the term "new drug." Delalutin is, in fact, a 
new drug under the Federal Food Drug and Cosmetic Act (FFDC) and 
is subject to regulation as such. For a more complete discussion 
of the drug regulatory scheme in the United States and the dif-
ferences between various provisions of the FFDC, see United 
States v. Article of Drug ... Hormonin, 498 F. supp:-424 (D.N.J. 
1980), aff'd o.b., 672 F.2d 902 (3d. Cir. 1981). 
9 
The respondent erroneously cited Rozier v. Ford Motor Co., 
573 F.2d 1332 (5th Cir. 1978), for the proposition that no public 
policy is served by excluding subsequently mandated governmental 
warnings. Rozier did not so hold. That case involved a motion 
for a new trial based upon Ford Motor Company's failure to produce 
on discovery certain memoranda dealing with the placement of the 
gas tank in various Ford Pinto models. In directing a new trial 
the Fifth Circuit found that Ford had been grossly negligent or 
contumacious when it withheld information concerning this issue. 
In dicta, the Court found that the federal exclusionary rule with 
respect to subsequent remedial conduct did not preclude these 
documents from being introduced in evidence because the documents 
themselves were prepared two years before the accident and thus 
were not remedial measures. The Fifth Circuit also observed in 
dicta that the material, if it had been made available to the--
plaintiff, might have been admissible as proof of subsidiary 
issues such as knowledge or feasibility. However, the Court 
concluded: 
We cannot know what use, if any, plaintiff's 
counsel would have made of the Trend Cost Esti-
mate had it been produced by Ford prior to 
trial. [Id. at 1343] 
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C. None of the Judicially Created Exceptions 
to the Exclusionary Rule on Subsequent 
Remedial Conduct are Applicable Here. 
The respondent argues that the improper admission of these 
FDA warnings can be rationalized on other grounds and thus any 
errors committed by the trial court were harmless. U.R.C.P. 61. 
She now urges this Court to approve the admission of this highly 
prejudicial evidence to establish the feasibility of conveying 
warnings and as proper impeachment and rebuttal evidence. The 
short answer to those suggestions is that this Court may not 
speculate as to how the trial would have proceeded had the court 
below correctly declined to receive this hearsay evidence. Those 
matters can only be dealt with at the retrial of this case. 
The respondent attempts to inject £easibility as a legitimate 
issue in this case. The record belies that suggestion. It was 
only after the jury verdict that the admission of these FDA-mandated 
warnings was seriously defended on this ground (Tr. 2623). 
The respondent suggests that Love v. Wolf, 58 Cal. Rptr. 42 
(Cal. Ct. App. 1967), permits the receipt of these FDA-mandated 
warnings on this issue. That case presents vastly different 
issues than exist here. In Love, a California appellate court 
permitted the receipt of subsequent warnings as impeaching evidence 
when various drug company officials contended that it was not 
possible to prepare clearer warnings. The Love case is emblematic 
of a number of decisions which have permitted subsequent warnings 
to be introduced in evidence where the clarity of a prior warning 
is a contested issue and the subsequent warning tends to establish 
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the feasibility of conveying a clearer warning. That issue was 
not present here. 
Here, Squibb contended that Delalutin was not a teratogen 
and therefore no warning was either necessary or appropriate. 
Squibb also argued that there was insufficient knowledge in July 
1972 for any responsible drug company to publish such a tera-
togenici ty warning. The information in the subsequently mandated 
FDA warnings addressed neither of those issues. 10 
10 
As previously noted there is no dispute that Squibb could 
physically publish a warning. Nor was there any issue raised at 
trial that Squibb failed to publish a clear warning. Thus the 
feasibility of doing either was never in dispute. 
To the extent it is suggested that it was feasible to discover 
a potential teratogenicity danger and to warn through labeling, 
the record reveals that no articles had appeared prior to the 
administration of Delalutin to the plaintiff's mother in July 
1972 suggesting an association between progestins generally and 
limb anomalies. The only literature appearing before 1972, cited 
in the subsequent FDA mandated warnings, dealing with any potential 
teratogenic effects of progestins was a one page letter from Dr. 
Isabel Gal in 1967. Gal, Nature Vol. 216:83 (October 7, 1967). 
This letter, in part, reported a statistical association 
between babies born with neural tube or spinal defects (not limb 
anomalies) and mothers who had been given hormonal pregnancy 
tests. It also observed that "[t]he possibility cannot be excluded 
that the difference significant at the 1% level between the two 
groups of mothers whom we questioned might emerge purely by 
chance." Gal, Nature, Vol. 216:83 (October 7, 1967). (Tr. 814) 
However, certain things were clear. First, the drug, a hormonal 
pregnancy test, a combination of progestin and estrogen, was 
different than Delalutin. (Tr. 812-813) Second, the progestin 
in these hormonal pregnancy tests was not Delalutin. (Tr. 818) 
Third, a basic error, obvious on the face of the paper, made the 
article biologically implausible. (Tr. 849) Gal noted, "[t]he 
average interval between conception and test was 5.6 weeks in the 
survey group [babies with defects] and 6.2 weeks in the control 
group." Gal realized that in order to have any meaning the drug 
had to have. been administered before the clo~ing of the neural 
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It is also evident that the respondent's potpourri of other 
grounds for admission, such as for impeachment and rebuttal 
purposes, are pretextual given the state of the record. 11 Since 
10 (Cont'd) 
tube. Gal did not know, however, that based upon the dates she 
reported, a large proportion of mothers in the survey received 
the hormones after the critical period where it could affect 
closure of the neural tube.. (Tr. 849) A subsequent publication 
by Oro Lowell E .. Sever of the Department of Epidemiology, Univer-
sity of Washington, Seattle, Washington, pointed out this obvious 
deficiency. Sever, "Hormonal Pregnancy Tests and Spina Bidifa," 
Nature, Vol. 242:410-411 (1973). (Tr. 848-849) 
Thus, it is clear that, while Gal reported an association: 
(l) by definition, and by her own admissions, it was not causation; 
(2) by her admission it could have been due to chance alone; and 
( 3) because of observation errors in the calculation of the 
timing of the birth defects, the study's biological plausibility 
was cast in doubt., (Tr. 849, 2410) 
The difficulties with Gal's work in fact were so pronounced 
that Dr., Allen Goldman, an expert witness for the plaintiff 
observed: 
I didn't discuss the validity of her 
work. In fact I don't think that neural tube 
defect data are that clear. (Tr. 2410) 
It is evident that both in reality and on the state of this 
record the Gal letter could not and did not provide Squibb with 
knowledge that progestins generally caused limb anomalies. It 
certainly did not establish the possibility of giving warnings 
and cannot justify the admission of FDA mandated warnings made 10 
years _after the appearance of the Gal letter. 
11 
Love v. Wolf, 58 Calo Rptr. at 42 stressed that the warnings 
were admitted for impeachment purposes and the jury was charged 
as to how those subsequent warnings should be considered by it. 
This also was the case in Incollingo v. Ewing, 282 A .. 2d 206, 222 
(Pa. 1971), where the Pennsylvania Supreme Court permitted the 
receipt of subsequent warnings.. There, the drug company had 
suggested that the warning in effect at the time the drug was 
administered was adequate. In permitting this evidence to be 
considered by the jury, the Pennsylvania Supreme Court stressed 
that "the jury was thrice instructed that the .... [subsequent] .... 
warning was not to be taken as evidence bearing on antecedent 
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the FDA mandated warnings were introduced in evidence during the 
respondent's direct case, Squibb had to confront them. 12 The 
error was made by the trial court during the plaintiff's direct 
13 
case. 
In sum, the plaintiff has failed to demonstrate any substan-
tial basis for admitting the FDA physician and patient package 
inserts in evidence. These documents once admitted were repeatedly 
11 (Cont'd) 
negligence. It is also important to note that in Incollingo one 
of the issues raised by the plaintiffs and presented to the jury 
was the fact that the ambiguous warning existing at the time the 
drug was prescribed was in effect cancelled when detail men from 
the drug company overpromoted the drug. None of these issues 
were present in this case. 
12 
The respondent inexplicably cites Givens v. Leder le, 556 
F.2d 1341 (5th Cir. 1977), and Reyes v. Wyeth Laboratories, Inc., 
498 F.2d 1264 (5th Cir. 1974), cert. denied, 419 U.S. 1096 (1974) 
as permitting the introduction~ subsequent warnings on the 
issue of causation. Barson Brief at 34. The respondent is 
simply inaccurate~ In Givens the Fifth Circuit approved the 
introduction of statistical reports from the Center for Disease 
Control, a United States government agency. The exhibits, the 
1971 and 1972 Annual Poliomyelitis Summaries, were not introduced 
to show that the vaccine in issue caused polio. Rather, the 
documents, which appear to have been statistical summaries, were 
introduced on the limited issue "of whether the medical profession 
recognized that vaccine-induced polio occurs." Givens v. Lederle, 
556 F.2d at 1346. It is important to note the court's observation 
that these statistical reports were admissible as public records. 
See Fed. R. Evid. 803(8). Further, the Fifth Circuit found the 
dOCuments could be referred to because the editor of the reports 
was "present in the courtroom, identified the documents, and was 
subject to cross-examinationo" Id. at 1346; Cf. Fed. R. Evid. 
703; ~ also State v. Clayton, 646 P.2d 723 (Utah 1982); U.R.E. 
63(15). The Reyes case also involved the admission in evidence 
of similar materials. 498 F.2d at 1264 
13 
In this Court the respondent now argues that the post-1972 
package warning inserts were properly admissible for rebuttal and 
impeachment purposes claiming that counsel for Squibb opened the 
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used by the respondent to improperly suggest that responsible 
public health officials had already determined that Delalutin 
caused birth defects. The admission of these documents altered 
the course of trial, required Squibb to meet this unexpected and 
improper evidence and led to the substantial prejudice complained 
of. The only appropriate remedy which this Court can grant at 
this stage of the proceedings is to reverse the judgment below 
and remand the matter for a new trialo 
13 (Cont'd) 
door during his opening remarks to the jury by suggesting Delalutin 
was both a safe and effective drug o Barson Brief at 31. A 
review of the trial record, however, shows that Squibb's opening 
remarks about the role of the FDA were quite limited and, taken 
in context, were appropriate in view of statements made by the 
respondent's counsel in his opening. Specifically, Squibb's 
counsel, in answering charges that necessary testing had not been 
performed on Delalutin before marketing by Squibb, responded 
that: 
The testing was in fact done, and in 1956 the drug was 
approved by the United States Food & Drug Administration 
for use in human beings for sale in our country, and 
indeed it was. 
In her argument to this Court the respondent contends that Squibb 
misled the jury by telling it that the FDA had approved Delalutin 
based upon safety datao D.Ex. 803, however, demonstrates that 
the FDA did in fact approve Delalutin for sale to the public in 
1956 after a review of just that. As noted in Squibb's initial 
Brief the FFDC in 1956 provided for the approval of new drug 
applications based on safety data aloneo 52 Stat. 1040 and 10520 
In 1962 Congress amended the FFDC to require the advanced submis-
sion of efficacy as well as safety datao 21 U.S.C. §§ 32l(p), 
3 5 5 ( b ) and ( e ) . 
It also should be noted that the package insert provided 
with Delalutin before that drug was first marketed in 1956 was 
approved by the FDA. 21 u.s.c. §§ 355(a) & (b) provides that no 
drug may be marketed in interstate commerce without that drug and 
its labeling first having been approved by the FDAo The respondent 
is simply incorrect when she suggests otherwise. Barson Brief 
at 5. 
-17-Sponsored by the S.J. Quinney Law Library. Funding for digitization provided by the Institute of Museum and Library Services Library Services and Technology Act, administered by the Utah State Library. 
 Machine-generated OCR, may contain errors.
POINT II 
THE JURY INSTRUCTIONS WERE AMBIGUOUS AND 
PROBABLY MISLED THE JURY AS TO THE PROPER 
STANDARDS TO BE APPLIED IN DETERMINING THIS 
CASE. 
This Court has determined that the elements which must be 
established in a products strict liability case and those necessary 
to establish a breach of implied warranty "are essentially the 
same . . . . Therefore, the same defenses discussed in strict 
products liability are available under breach of implied warranty." 
Ernest~· Hahn, Inc. v. Armco Steel Co., 601 P.2d 152, 159 (Utah 
1979). The Restatement of Torts (2d) § 402A comments h, j, and 
k, which deal with the application of the principles of strict 
liability, dictate that in a prescription drug case the failure 
to warn is to be judged by traditional negligence concepts. That 
duty, by definition, can only apply to dangers which the company 
knew or should have known about through the exercise of reasonable 
care. See Squibb Brief at 56. 
It is clear that because of the multiple, repetitive, and 
ambiguous instructions which the trial court gave the jury, no 
one can determine with certainty that the jury did not impose a 
standard of absolute liability upo.n Squibb. 14 Apparently, all 
14 
The respondent suggests that the appropriate standards to be 
applied in a strict liability case were given when the court 
provided the jury with Instruction Nos. 23 and 24. See Barson 
Brief at 36. What is clear from the placement and content of 
these charges, however, is that they dealt with the question of 
negligence. Since the trial court charged all three theories and 
provided separate instructions for each, this tended to emphasize 
the incorrect strict liability charges rather than minimize them. 
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the parties in this proceeding agree that it would be inappropriate 
to judge Squibb based on such a standard. 
Instruction No o 25 which represents a strict liability 
charge in the abstract, is completely inapplicable to this prescrip-
tion drug case and, when read in conjunction with Instruction 
Nos. 26 and 27, would appear to erroneously convey to the jury 
that it could hold this defendant responsible should it find that 
Delalutin caused the plaintiff's birth defects, independent of 
15 Squibb's ability to know of these dangers. While such a presump-
tion may be appropriate under other comments to the Restatement 
of Torts (2d) § 402A, it is inappropriate in a prescription drug 
case. When Instructions Noo 18 and Noso 25 through 29 are read 
as a whole it is obvious that a jury may well have imposed liability 
if it simply determined that Delalutin caused the birth defects 
complained of. 
The proposed Instruction which Squibb requested the trial 
court give (Proposed Instruction lOA) eliminated these ambigui-
15 
We agree with the respondent that the jury instructions must 
be considered as a whole and no particular instruction or parts 
should be considered separately or given undue emphasis. We also 
agree that were the only flaw in these instructions the unnecessary 
duplication or replication of an idea reversal would not be 
required. 
Actually Woodhouse v. Johnson, 436 P.2d 442, 445 (Utah 1968), 
cited by the respondent, observes that while duplication of an 
idea in the instructions is not reversible error it is best to 
avoid repetition where possible. Here the unnecessary repetition 
was highly prejudicial because its effect was to lead the jury to 
assume that strict liability, breach of warranty and negligence 
all presented different issues for their resolution. As we have 
seen, this is simply not the case. 
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ties by instructing the jurors that "you can find Delalutin in 
question to have been in a defective condition, unreasonably 
dangerous only if you determine that Squibb failed to warn .•.. " 
Appendix B (emphasis added). In Skaggs v. Clairol, Inc., 85 Cal. 
Rptr. 584 (Cal. Ct. App. 1970) , a California appellate court 
found in virtually identical circumstances that the Instructions 
were so ambiguous that "the jury could believe that plaintiff's 
right to recover damages from defendant was dependent solely upon 
showing .•. (defect)." Skaggs v. Clairol, Inc., 85 Cal. Rptr. 
at 588; Cf., Smith v. ~· Squibb~ sons, Inc., 273 N.W.2d 476 
(Mich. 1979); Ortho Pharmaceutical £2E.E.· v. Chapman, 388 N.E.2d 
541, 552 (Ind .. Ct .. App. 1979); Rainbow v. Albert Elia Building 
Co., .!a.£., 373 N .. Y.S.2d 928 (N.Y. App. Div. 1975). 
The respondent has totally failed to address this serious 
ambiguity in the jury Instructions. Since Squibb properly objected 
to the failure to give its Proposed Instruction lO(a) and since 
the trial court's failure to do so substantially prejudiced the 
appellant, it is entitled to reversal of the judgment and a new 
trial. See, ~·, Quarry v. Waters, 588 P.2d 702, 704 (Utah 1978). 
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POINT III 
THE RESPONDENT FAILS TO ADDRESS THE ARGUMENT 
BY SQUIBB THAT IT WAS ENTITLED TO A DIRECTED 
VERDICT ON THE ISSUE OF TERATOGENICITY TESTING. 
The defendant moved for a directed verdict on the first 
count of the Complaint (negligence) as it related to negligent 
testing at the close of the case. Squibb observed that no evidence 
had been produced to show that were animal teratology testing to 
have been done it would have probably provided information demon-
strating the defects alleged (Tr.2440, 2442, 2596). The applica-
tion was denied by the trial court. 16 
The respondent has completely missed the thrust of Squibb's 
repeated arguments that the issue should not have been presented 
to the jury. Each of the plaintiff's own experts observed that 
there was no assurance or even likelihood that had animal tera-
tology studies been initiated they would have disclosed Delalutin's 
teratogenic potential. 17 See Squibb Brief at 70-72; l; Frumer & 
16 
Thereafter, Squibb objected to the jury instructions dealing 
with negligence for the same reason (Tr.2578-2579). The defendant 
later raised the issue when it moved for judgment nov. and a new 
trial after the jury's verdict (Tr.2595-2596, 2631). Squibb 
raised the issue again before this court in its initial Brief. 
Squibb Brief at 66-72. 
17 
While Squibb has sought to avoid distracting this Court from 
the important legal issues here, the repeated references in the 
Barson Brief to masculinization or viralization requires some 
response. Respondent, for example, refers to the fact that there 
were numerous revisions in the physician package insert between 
1956 and 1979. Barson Brief at 5. Many of these changes are 
irrevelant to the issues in this case and deal instead with new 
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Friedman, Products Liability § 601(1]. As noted by the New York 
Appellate Division in Buria v. Rosedale Engineering~., 184 
N.Y.S.2d 395, 397 (N.Y. App. Div. 1959), where a plaintiff's 
theory involved a failure to test "negligence [is] still not 
established unless it be shown that proper testing would have 
disclosed the ... (product] to have been defective." (Emphasis 
17 (Cont'd) 
medical uses for Delalutin such as the treatment of endometrial 
cancer (P.Ex. lO(s)), something for which the drug is currently 
used. 
However, insofar as the package inserts relate information 
on the possible masculinization of female fetuses, they simply 
reflect Squibb's efforts to report information as it became 
available. Sporadic cases of virilization, which can occur 
spontaneously, in patients receiving Delalutin did not establish 
a "cause-effect" relationship as noted in the FDA-approved package 
insert of 1966 (P.Ex. lO(h)). The 1970 revision in the package 
insert did nothing more than make a more generalized statement 
concerning progestins; it did not, however, change the earlier 
statement that determinations regarding cause and effect were 
"inconclusive" (P.Ex. 10(1)). 
Insofar as masculinization is concerned, the evidence available 
to Squibb showed that tests of Delalutin indicated it to be 
non-virilizing and non-androgenic. Even Dr. Alan K. Done acknowl-
edged that Dr. Leonard Lerner's study showing Delalutin to be 
non-androgenic was a good one insofar as testing for virilization. 
(Tr.769) Additionally, the plaintiff fails to note in her Brief 
numerous other articles cited in this record which indicated that 
Delalutin did not cause virilization or masculinization. Thus, 
the many references to virilization and masculinization which 
suggest that this has a bearing on teratogencity and/or testing 
are misleading. Indeed, the admission of substantial testimony 
on masculinization, to which Squibb took objection, in all pro-
bability only served to further confuse and mislead the jury. 
(Seen. 18 and.19 infra.) 
One final observation is, perhaps, appropriate to highlight 
the apparent confusion existing in the minds of plaintiff's 
counsel. They make reference to the testimony of Dr. Allen 
Goldman and the articles which he cited to support the submission 
of negligent testing to the jury. Aside from the fact that many 
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in original) . This expression of the principle of proximate 
cause has been accepted by this Court in Northern v. General 
Motors .£2.!:E.., 268 P.2d 981 (Utah 1954). 18 
17 (Cont'd) 
of these articles deal with the question of masculinization, 
several of the articles dealing with the subject of teratogenicity 
are incorrectly cited by counsel as supportive. Barson Brief 
at 11-14, 17. For example, in the article by Andrews and Staples 
cited by plaintiff, the authors concluded that: "Our study on 
MPA [Provera (another progestin)] did not support the clinical 
observations of Nora and Janerich, for example, regarding MPA, 
since no significant increase in gonad dipgenesis, heart defects, 
or limb deformaties were seen after MPA exposure to any of the 
test specieso" "Prenatal Toxicity of Medroxyprogesterone Acetate 
in Rabbi ts, Rats, and Mice, 11 Teratology, 15: 25, 31 ( 1977). such 
evidence hardly proves that the alleged failure to test was the 
proximate cause of anything. 
18 
Squibb has focused on legal errors and has sought to avoid 
drawing this Court into scientific discussions or arguments. 
Plaintiff's comments concerning the so-called Deladroxate study, 
however, require some response. Barson Brief at 400 
The defendant had objected to the introduction of evidence 
concerning Deladroxate, an injectable form of contraceptive, 
composed of both estrogen and progestin (other than Delalutin) 
and never marketed to the public (Tr. 751). The objection was in 
part based on the fact that Deladroxate included estrogen, a 
totally different family of sex steroids from progestins (Tr.749-
750). Dr. Alan K. Done, as plaintiff's expert, had previously 
testified that estrogens, which are very different from Delalutin, 
were a potential confounding factor and that he had made an 
attempt to eliminate studies involving estrogens (Tro869; 875, 
876). Nevertheless, the Court admitted P.Ex. 530 and permitted 
Dr. Done to testify about the Deladroxate studies. 
In discussing these studies on appeal, the plaintiff exhibits 
a serious confusion which marks some of her other factual recita-
tions. See, Reply Brief at 23 n. 17 supra and 19 infra. For 
example, the study on rabbits did not reveal any "rabbit offspring 
being born with their hind legs misplaced, their skulls misshapen, 
and other skeletal defects." Barson Brief at 40. 
Plaintiff has, presumably inadvertently, lumped together the 
findings from the study involving rabbits with the findings from 
a separate study involving rats. "Perinatal and Postnatal Study 
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While Squibb strongly disputes the claims that it should 
have engaged in further animal testing with respect to Delalutin, 
its argument that it is entitled to a directed verdict does not 
depend on this contention. There was insufficient evidence to 
present the plaintiff's theory of negligence based on animal 
testing because the evidence failed to establish proximate cause; 
that were such testing done, Delalutin's teratogenicity would 
probably have been discovered. Squibb was entitled to a verdict 
on that issue. Since the jury rendered a general verdict in this 
case after the Court had instructed it on the theory of negligence 
based on a failure to test, we cannot know whether the jury found 
for the plaintiff based on this theory. Under these premises 
Squibb must be granted a new trial. 
18 (Cont'd) 
in Rats" (P.Ex. 530, P. 00036). The study in rats was not a 
teratology study. In the rat study where the misshapen skulls 
and other skeletal defects were noted, the Deladroxate was given 
beyond the time when it could affect the development of these 
structures. This was precisely the opinion of the authors of the 
study who concluded that the malformations "probably were caused 
by prolongation of gestation and/or intrauterine death" (P.Ex. 530, 
p. 00041). 
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POINT IV 
THE RESPONDENT FAILS TO ADDRESS THE ARGUMENTS 
MADE BY SQUIBB SUGGESTING THAT THE TRIAL COURT 
ERRED IN: (1) NOT EXCLUDING EFFICACY EVIDENCE 
AND (2) PERMITTING P.EX. 58 WHICH CONTAINED 
IMPERMISSIBLE SUMMARIES OF DRUG EXPERIENCE 
REPORTS TO BE RECEIVED IN EVIDENCE. 
A. Efficacy Evidence 
The respondent argues that efficacy evidence is necessary in 
order to employ the.risk-utility analysis contemplated in comment k 
to the Restatement of Torts ( 2d) § 402A. For that reason she 
suggests that efficacy evidence was appropriately received by the 
trial court. A review, however, of the Instructions given the 
jury discloses that no information was provided on how this 
risk-utility analysis should be employed. Indeed~· the record 
reflects that the plaintiff never asked the trial court to charge 
the jury with respect to the use of risk-utility analysis or the 
application of comment k. 
As is evident from a review of the Statement of Facts provided 
by the respondent to this Court, efficacy evidence was routinely 
confused with safety evidence. 19 It was also used to suggest that 
19 
The profound confusion this evidence must have caused as the 
jury sought to resolve the issue of causation--a question of the 
drug's safety--is exemplified by the Statement of Facts in the 
Respondent's Brief. Barson Brief at 9. There, the respondent 
suggests that two letters admitted in evidence over objection by 
Squibb and written a year after Mrso Barson received Delalutin 
forcibly demonstrate Squibb's indifference to teratogenic testing. 
(P.Ex. 731; P.Ex. 736) What is apparent from a review of these 
trial exhibits, however, is that they have nothing to do with 
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Squibb had failed to engage in teratology testing--an entirely 
different category of tests. The plaintiff now asks this Court 
to accept this efficacy evidence and apply a risk-utility analysis. 
Accepting such an invitation would make this Court the ultimate 
finder of fact and render trial to a jury a meaningless exercise. 
19 (Cont'd) 
teratogenic testingo Rather, both letters deal with the decision 
by Squibb not·to fund an ongoing study at Johns Hopkins Medical 
School testing the efficacy of Delalutin for another medical 
indication.. As the evidence at trial amply demonstrated, it 
would be highly unethical and improper to conduct teratogenic 
testing on human beings and, of course, were the proposals to 
have suggested such testing, Squibb would have properly rejected 
them .. 
In discussing Squibb's reluctance to undertake funding this 
efficacy study, Dr. Kendall, then Associate Medical Development 
Director at Squibb, noted that since his last visit to Johns 
Hopkins University Hospital "the FDA has announced that it will 
publish a Federal Register Statement warning against the use of 
progesterone in pregnancy .... Right or wrong, that is now the 
FDA's opinion O••" (P.Ex. 731). Because of the expected FDA action 
withdrawing Delalutin's pregnancy related indications as well as 
various economic considerations, Dr. Kendall again wrote to the 
physician conducting the study in September 1973 advising him 
that Squibb funding for such an efficacy study was unlikely given 
the expected FDA action. Again, rather than reflecting Squibb's 
indifference to teratogenic testing, the letter demonstrates just 
the opposite·. Dealing with the efficacy question, Dr. Kendall 
observed: 
Perhaps if work like this had been published 
a few years ago, FDA would be looking at 
Delalutin in a more favorable light. Indeed, 
from what you tell me there does seem a 
chance even now that they will reconsider. 
[P .Ex. 736] 
The plaintiff's counsel, oblivious to the content of these 
letter exhibits, erroneously observes that these exhibits "cer-
tainly establish the background and facts with respect to terato-
genicity as they existed prior to the injection of Delalutin in 
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Beyond a few isolated transcript references purportedly 
supporting the introduction of this evidence, the respondent 
offers no basis other than conunent k for its receipt. Instead 
she seeks to distinguish Needham v. White Laboratories, Inc., 639 
F.2d 394 (7th Cir. 1981), cert. denied, U.S. , 102 S.Ct. 
427 (1981). 
While the respondent is correct in observing that the reversal 
was predicated on the improper jury instruction, it is undeniable 
that the Seventh Circuit found that efficacy evidence was inappro-
priately received by the trial court. That court specifically 
observed: 
The drug company's defense throughout 
this case has been that it did not know of 
the dangerous propensity of ... [the drug]. 
No warning accompanied the drug. Thus, 
comment k, by its terms, could not provide a 
defense in this case ~ ... Because [the drug 
company] failed to warn, comment k could not 
apply in this case, and evidence of the 
efficacy o"r inefficacy, of [the drug] ~ 
irrelevant. [Needham v. White Laboratories, 
Inc., 639 F.2d at 402] 
Since the efficacy evidence was irrelevant and was improperly 
used to suggest Squibb's negligence in failing to conduct tests, 
19 (Cont'd) 
Kathy Barson." Barson Brief at 9. Since this suggestion is 
contained in the respondent's Statement of Facts under the heading 
11 FACTS OF SQUIBB'S FAILURE TO PERFORM TERATOLOGICAL TESTS, 11 the 
clear confusion in the mind of counsel for the plaintiff between 
efficacy and safety testing demonstrates the serious prejudice 
which can be produced when questions of efficacy are injected 
into a case dealing with causation--a question of safety. Counsel 
for Squibb predicted that such confusion was likely to arise in 
the minds of the jurors should such irrelevant and potentially 
prejudicial material be introduced in evidence (PR. 63-64). 
Counsel for the plaintiff has now demonstrated how easily such 
confusion can arise. 
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this evidence "probably had a substantial influence in bringing 
about the verdict " U.R.E. 4. As such, Squibb is entitled 
to a new trial. 
B. The Drug Experience Reports. 
The respondent makes no attempt to seriously defend the 
introduction of P.Ex. 58 containing a summary of inadmissible 
drug experience reports (DER's) concerning Delalutin. As noted 
in Squibb's initial Brief, DER's represent anecdotal accounts of 
experiences with drugs which are forwarded to drug companies by 
various individuals including health professionals, lawyers, 
consumer groups, and the general public. Squibb Brief at 13 and 
79-86. The law requires that drug companies routinely forward 
these DER's to the FDA regardless of their source. 21 u.s.c. 
§ 355(j); 21 C.F.R. § 310.300. 
In Muhlenberg v. Upjohn Co., 320 N.W.2d 358 (Mich. Ct. App. 
1982), a Michigan appellate court recently found that DER's were 
inadmissible hearsay and not subject to the business records 
t . 20 excep ion. The trial court also properly excluded the DER's on 
20 
The Muhlenberg court found that 
The reports doctors submitted can be ana-
logized to information procured in a survey. 
Where surveys are submitted under the business 
record exception to prove the truth of the 
matter asserted, they routinely are excluded 
as being nothing more than a compilation of 
hearsay. Unless the .techniques used in 
conducting the survey are established scientifi-
cally and the survey results are objective 
and representative of the pool survey, the 
survey lacks the guarantees of trustworthiness. 
[Muhlenberg v. Upjohn Co., 320 N.W.2d 358 
(Mich. Ct. App. 1982)] 
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that basis, however, it then inexplicably permitted the witness 
to testify as to their contents in summary form, in contravention 
of U.R.E. 70. Squibb Brief at 82-84. 
The respondent incorrectly cites Needham v. White Laboratories, 
63 9 F. 2d at 403, as supportive of this improper procedure. 
Needham holds to the contrary. There, the Seventh Circuit observed 
that "before a summary is admitted, the proponent must lay a 
proper foundation as to the admissibility of the material that is 
summarized .. " 639 F.2d at 403 .. As is evident from review of the 
record, such a foundation was not laid. Squibb Brief at 79-81. 
Since the summarized DER' s produced virtually the only 
implicating evidence against Delalutin in P.Ex. 58, it cannot be 
said that the admission of such evidence was harmless. Squibb is 
entitled to a new trial based upon this substantial error. 
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CONCLUSION 
For the foregoing reasons, the defendant respectfully urges 
that this Court vacate the judgment and remand the matter for a 
new trial on all issues. 
Respectfully submitted, 
CHRISTENSEN I JENSEN & POWELL 
Attorneys for Defendant E.R. 
Squibb & Sons, Inc. 
By:---'-!-_u...__/ ____ _ 
RAY R. CHRISTENSEN 
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SAFETY ANO EFFICACY OF PROGESTERONE ANO 17~ALPHA-HYOROXYPROGESTERONE FOR THE 
TREATMENT OF REPRODUCTIVE OISOROERSo 
An overview and •ne po•en+:a1 benefits of progesterone and 17 hydroxy-
progesterone for trea""meni' of pregnan+ or potentially pregnant women was 
presented by Willian Andrews, MeOo, a c:ommi't_'1'ee member, Oepar+ment of 
Obstetrics and Gyneco I ogy, Eastern Vi rg t n i a Medi ca I Co 11 ege;; _ -
Trea~en+ of documented luteal phase defec~ in infertile womeR and women wi~n 
a hi"s+ory of habi~ual abori'ion have achieved successful pregnancy with 
adminis1"ratton of suppfemen1"al progesterone or 17-=0H progesterone..- - In a 
double bltnd s~udy women with habitual abortion treated with 17-0H 
prog9sterone had a 73% live biri'hs compared to 46% tn the placebo-group. 
· In ~he· Fepor"~S cf~ i ng ~he t neff t cacy of progesterone supp I emen-rat ion for the 
preven-!"ion of fetal was-t-age in women w·i'f"h ~ his-t'ory of habitual abor-tion, 
investiga~ors utilized either lowered pregnandiol levels for diagnosis, a 
crt~eria that varies with metabolism of progesterone, and started-progesTerone 
'i-herapy aH'er +t;e seven~h week of pregnancy, too late -to expect benefii"s of 
progesterone, or administered progestins that produce a luteolytic effect. 
While progesterone is no longer employed for pregnancy testing, tt~ use in 
evafuaTfng primary and secondary ~enorrhea considen~bly Feduc:es 't't'H~.tLme anct 
expense of diagnosis and •rea'i'men+o 
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Those hormone prepara"l"ions wtth repor-fed terai'ogenicity are usuat.ly 
es+rogen-progesterone combina•ion products. Repori's of teratogencity with· 
proges1"ins are derived mos1"1y from a I imited number of cases., 
The Collabora-t-ive Perinatal Project did not detec1' an associa-t-ion bei'ween 
either progesterone or hydroxyproges'terone use and congenrtal hear-t- d1sease, 
the VACTERAL syndrome, or limb reduci'ton, but did observe a sign~fican"I" 
increase of bir.,.h anomalies with medroxyproges"l"erone acetate-and noreth1ndrone 
OespiTe +he Obs•etr!c and Gynecology Advisory Corrrnittee':S.~ecommendation,-'fhe 
Bureau of Drugs incJuded progesterone and hydroxyprogesterone among the 
progesta•!onar agen.,.s contraindica~ed for use in early pregnancy. 
Par1"tcfpants at 'the American Fer1"i I ii'y Associa1"ion sponsored symposium-
suggested thaT the human ova is exposed to concentrations of.endogenous. 
proges1"erone and hydroxyproges1'erone in the ovary and during: transpor1" through 
~he hlJopian +ube grea-t-er than the suggesi"ed therapeutic-doses, and there are 
differences tn the chemical and biologi·ca·I effec1"s between of na1"ural 
proges+erone and synthei"ic progestins. 
Or. Andrews concluded 1-ha~ while medroxyprogesterone, norethindrone and 
e•l'I i sterone may be 1-erai"ogen i c, he does no+ bel i eve that there is valid 
ev i denc:e of proges~erone or 17 hydroxyproges1-erone. teratogenic i ty. and when-
properly indica•ed, use of these steroids are of significant benefit. 
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The biological activi+y of different sTrucTural classes of progesTaTional 
agents was reviewed by Len Lerner, PhoOo, Qepar-tmen+ of ObsTeTric:s and 
Gynecology, Thomas Jefferson Universityo 
Whfle al I progesta1"ional agen-ts, Ca> s1"imula-t-e developmen-t' of endome~ial 
glands Cb> maintain pregnancy In some species of ovariec~omized animals, and 
(e) exhlbi"" anti esi'rogenlc properi"les,, their o-ther physiologic ettects, i o-e-o 
ancf"i.., androgenicsi ACTH s-timulation, cor1"isone I ike ac:tivrry, are variable .. 
The pr-oges'f-ai"fonal agen1"s are ac1"ual ly different cl asses of chemical compounds-· 
wi~h differen1' ra-t-es of me+abol ismjl excre-tion, and pa-tterrrs o_f ctiS'fribu'fJon_ in-
the body.. t n an trna I s-tud i es nore"f"h i ndrone and medroxyproges+erone, but- not 
progesterone or Oelalu-ttn, have been repori"ed to affec:'f fet'al maseu-1 inizatlon.,-
lrtjec-tion of Oefali.rtfn main~ained pregnancy tn monkeys with i'hreatened 
abOf""'° ion and no fe1'a I anoma J i es were observed anong rats_ 'treated w i ~h 
proges.,.erone or Oe·I ah.rti n durl ng pregnancy., 
Franz Rosa, ~o0. 8 Qivision of Drug Experience, Food and Drug Adminis'fration, 
commen~ed on the adverse drug reac1"ions repor1"ed to the F-OA- an-d •ne 
epidemiologic: s-t>udies concerning the use of progesta1"ional agents and ~ir'*'h 
anoma I ies .. 
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Qf the computerized 120,000 adverse drug reactron reports ,..ecetved by the FQA-
there are about 700 terai"ologf cal obs@f"'vai'ions, 187 o+ which are associated 
with progesi'fn COntafnJng drugs .. Most of the gf9nftal defeci'S t"91)0r"Ted Wef"'fl) 
wtth Provera use, and many reports of anomal les attr-ibui"ed- to pr-og.,sttns wer"e 
con•ounded with the us& o+ progestln and es1"rogen mfxtur-es. 
Whtie the grouping of case control and cohort studies suggests a +airly stong 
r"'ef attonshlp between fetat sex no-mone exposur-e and hypospadias, the lack of a 
denominator pr-event's thP. calculatlon of an fncidence rate. Tne assocfatioo o~ 
~ex hcrmones with hypospadfas Is ltmited to progestln exposure to comoination 
with -estrog1tns, t .,e. gestest, oral contr-ac::epttves, and ts pr-obaoly due to the 
tnf luence of esfrr.>gen r-ather than progestlnsG 
The evldt9nc:e=a o'*' an assodation between non genttal malfor-matlons and exposure 
to progestatlonal compounds was ~evtewed by Robert Brent, M.o •• Ph.D.,. 
Qepar-i'meni' of Ped r a1"r t cs, . Thomas Jefferson Un t vers I i:y. 
Followlng concP.ptlon, there- ts a forty percent chance that a majo,.. 
mar 4 r.rmatt on or- anomaly. b r ocheml cal or- anat°"!t cal, wl 11 occur. _The causes of 
human mal •or-mat Ions ar-e multt factored. Cytogenetlc err-ors acr;ount for about 
5S of- anai'omfcal malformatfons, 20%. al""e duP. ·to autosomal gem:.tic causes and 
65% are fr-om P.ftner a.multffactor-tal etiology or- spontaneous err-ors in 
embr-yogP.ne~!s. ThA ramalnlng 10% can be accounted 'or- by environmental 
+actors, f .e. rn•ecttons, dr-ug~, high dose radlatfon. 
ThP. I net dP.nce "f spec [+I c ma I +ol""matf ons cannot ~e detP.rmf ned •rom i"nP. advPf""se 
·J drug r-eacttons r-Aport~d to the Food and Qrug Admlnistr-atlon because o+ th~ 
gr-19a+ ~xpo!=urP. ~o the dr-ug and the commonnP.s~ o• th~ anomaly. 
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Only one cohorT STudy, the Col laborattve PertnaTal ProjecT, associated use ot 
progestattonal agenTs with non-gani~al malformation among many reported 
negative sTudies with. regard t~ non geniTal malformationso Most of the 
postttve data.originated from case c:on"frol studies 0 individual physicfans 
STudying a small populationo that perhaps ignored the significance of clinical 
teratology and/or geneticso 
Teratogenic effec~s, unlike muTagenic changes, exhibit a dose response 
'threshold effec"f"; for exam.ple 9 The app~arance of an anomaly when the 
e,q)erimen-t-al animaf has received 50-100 times the 1'herapeutfc doseo 
Some pcrren+i~I errors in epidemiologic investigations of teratogentcity are: 
~ the unknown incidence of a malformatfon, the low exposure rate of the ) 
~· -
) 
conTrols. ignoFing the Importance of the exposure period; Including in the 
STudy malformations an etiology unrel~ted ~o the alleged teratogen1 ignoring 
confound1ng hc:'f>ors and nega'i"ive .epidemiolog.ical s'tudtes-and. finally, 
suggesTing· a causal tty tliai" doesn't make biological sense .. 
In Levy's 1973 study some children were exposed ~o other hormones, i.eo 
insul inf thyroid, the au~hor also did not corroborate the date of-exposure and 
used an tnapproprtaTe con+rol groupg 
The Hal+rap s~udy ignored the negative effect of steroids on birth defects and 
tn their pub I ications included the caveat 19an excess of malformations would oe 
expected among babies born to mo~hers with threa-t-ened or previous 
miscarl""iages, whe.,.her or nc:rr they were given hormonesn .. 
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The-Heinonen s-t-udy, on addittonal revfew, indicated tha-F 5 of the 19 cases of 
cardiac anomalies were exposed after the period of cardiac organogenesis: wni le 
some eases of malformation sugges't the involvement of envJronmen-tal or gene1"-ic-
fac:Tors.,. 
In a recen-t- publica-t-ton Nora s+ated tha1" memory bias may have affected his_- --
da~a, and Or. aren't' suggesi"ed or. Nora's use of an inappropria.te con1"roJ group 
and method of analysiso 
In summarizing the I i~errure, 1"here are many more repor-t-s that~ -di~ no-t-- - ~ 
demons1"ra?e an association of steroid hormones with non gen-i-t~a-1 maltor~J'Jon _-
than dido None of the claimed posi•ive associa1"ions were related to a -- -
par-t-icular -type of hormone. The populcrtions si"udfed were smaJI ·in compariso_n 
To the 1-o"!"af number of exposures and •he per lod of exposure- dur i-ng ges1"-a1"i on, 
when exogenous hormone exposure was pos~ibly associated wi~h JTtal_forma~ion-, was=. 
1-oo broad for induc+fon of 1-he repor-!"ed mal forma'tions • - There was no 
cons i s+en'+' type or pattern of def ec+s or any ind i ca1" ion _ot a dose- response 
rela1"fonship., 
There is data sugges'ting thaT bleeding in early pregnancy and ~hraatened 
aborTfon are themselves associai"ed wi'i"h an increase of malformed -i-nfani"s-. 
Cessa• f on of 'the use of s~ero f d pregnancy 'tests has not had -an effect on the 
overal I number of reported malformations. 
The criTeria necessary -t-o establish an agen1"'s teragogen-icity are: 
I. A majority of the epidemiological s~udies must demons~ra~e an increased 
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Incidence of malformattons tn the exposed population. 
2 .. The eptdemlotogrc s1"udl~s should demonsi'r'ate an Increased Incidence ot a 
parTtcular group ot malfor-mattons, t.ec rubella, thalidomide. 
3 .. It should b8 posstole to demonstrate t~atogeniclty in an animal model, 
except for vfrusesc 
4 .. Th94""e should be some type o+ a dose rela~lonshlp bet'llJP.en the amount o~ 
P.xposurl! and the drug,, 1 .. eo an Increase tn the dose ln animal -studies- is 
accomp ant P.d by an t no-ease t n t net denc:e .,_ 
5~ There must bP. a scJentittc: explanation for the eff4'Cta 
· The eurFeni' data as sod at-1 ng progesterone as ~ ter=- atogen does not meet the 
above crtter-ta. It Is dlHlcuit to consider" progesterone as a ter-atogen 
because o• thP. h I gh prog.esterone 1 eve t s to wh I ch the embryo i s exposed dur i ng 
deve I opmen to 
The current' labP.I Ing ~or proges1'ationat dFug pFoduc:t's should be more specific, 
and cl tntcat ly appFoprtate. QI"".,- Br=ent Is convinced that progesterone and 
17-0H progP.i:ctEYonP are not ter'atogentc and th& F(sk associ.at_eid with '!'hP.ir use 
-Is I ess than the spon-raneous Ft sk with T nadvertP.nt usP o'- oral contracept Ive 
Jn f!ar'" t y pr-egnaney $ 
Or. Brent' ~uggP.sted lab~ltng changes ~or progestatlonal drug products shculct 
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tnc:Jude the s1"a1"ement': "Although This drug has no-t- been proven safe for the 
developing embryo, the risk of embryo or fe1"al pa-f"hology with therapeutic 
doses would not warr-anT- an f nt'erruption of pregn·ancy in a -wanted pregnancy 
since +he spon~aneous ,..isks are much grea-t-er". 
Or .. John Rock, Johns Hopkins University School of ~edfcine, pr"eseni'e~ 
epldemiologic da1"a from ~hree hundred pa~ients -t-reated with progesterone or 
f7-hydroxyprogesterone from the tfme of the elevation of basal body - -
-temperat'ure and c:on1"inued for six weeks or, in some cases, througnou1"-tne 
entire pregnancy. He compared the ra+e of bir~h anomalies-to a confrol- group 
and was unab f e to de1"ec1" a sf gn if i cant number of chi J dren w i ttt e i-fner --tne 
VACTERAL syndrome, or J tmb reductions. 
- The eff icac:y of progesterone and Ii-OH progesterone caproafe ~for preventing 
the onse'f'> of prema1"ure labor,, the e-tiofogic fac~ors assoCiated :wii"n pret-er-m 
I abor and '!"he -t-eratogen i c risks of this therapy was d t scussed by ·John Johnson, 
~.D .. ,, Johns Hopkins University Medical Schoolo 
A medical his-tory of pre"f"erm delivery and of repeated spontaneous miscarriages 
is us_ual ly associated with l"'isk of additional preterm delivery in subsequeni' 
pregnancies. 
In a prospec:1"ive double blind placebo control led study, treated patients had 
less preterm def iveries, greater bir+h weight babies and a fower perinatal 
mor1"al ity than ~he con•rol group. 
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The difference tn the rate of prematurity during a second study of t~eated and 
un~reated pa.,.ien.,.s was less than differences between trea•ed and placebo 
control led patients, perhaps due to the beginning of trea-mtent after the 
sixteenth week of pregnancy and limiting the amount of medication to 250 mg/ 
week o In a doub I e b I f nd prospect- ive si'udy of pat I en'i"s treated with 
17-hydroxyprogesterone, women carried their pregnancy slgnlficantly longer and 
had grea'f"er bir"l"h weight babies than women treated wi'th the beta agonist' 
ri+odrineo 
In an attemp1" to det'ermt ne the effects of. 17-0H proges1"erone, no- differences 
in serum levels of es+rogen, c:orticoids, epinephrine~ norepinephrine, 17 OH 
proges.,.er-one or pros1"aglandin metabolites were identified among ei't'her term or 
preTerm del lveriesc However» the serum levels of .progesterone and urinary 
pregnandiol were significantly lower prior to preterm del fvery suggesting an 
etiologic role of progesterone.. The tc:r~-al frequency ot congen·ital· anomalies 
be~ween T-rea1"ed and un•reaTed pa•ien~s at high risk for pre1"erm dei ivery is 
simf lar w·i+h no chromosomal or congenital anomalies observed .. 
Or .. Johnson be Ii eves tna-r the Food and Drug Admi n i s"N"a"f ion rs conterrt ion 1"hat 
proges•a~ional agen~s are teraTogenic had hafted research with this class of 
drugs for ~hose ind i c:a1" ions and he expressed •ne hope that the comm·i t~ee w i I I 
consider ~he new da+a under recommendai"fono 
Ron Gray 6 PhoO., Oepar1'men+ of Population Oynamicsp Johns Hopkins Hospital, 
reviewed the li1"erature of the teratogenic potential of progestin, the 
etiology of bir~h defec~s, the clinical use of progesteronep and the 
inconclusiveness of epidemiologic studiesa 
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A human tera1"ogen can be i dent it i ed by an abrupt increase irt i"he incidence- of 
a par-t'icurar detect coincident ~i.,.h a known environmen1"al change during early: 
pregnancy with the absence of o1"her factors common to al I o1"her pregnancies 
which yield infants wfth characteristfc defectse 
Cf inicaf exposure +o proges1"in compounds,. nai"ural or synthetic. in early 
pregnancy may be due to con1"raceptive hi I ure,. Treatment for I u'teal phase 
defec+., pregnancy 'f"ests or' adminis-t-ration for the preventfon--of tnraai"ened -
abortion or prema+ure labor. 
To de+ermt ne teratogenic etfec-t- of proges-t'erone compounds The exposure mus1"-_ 
coincide with a c:r-ttlcat phase of fetal development, women mus_t be awar~ of 
-the drug used, the cta-!"a mus1" noi" be grouped in an arbitrary fashion and -
confounded wi'th multiple rfsk fac1"ors,. l.eo., age. geogr-ap_nic 1-oca-tion.- 'the -use 
of oTher drugs, and exis+ing medicaf conditions, mus"!" be accoun1"ed tor. 
The rne"f"hods of epidemiological experimental design are: CI:) the case- control 
study in which exposed children are ma1"ched wi'th contr-of children contains 
re+rospective uncertainty and has potential recal I bias C2>a prospective 
cohor1" study investigates the frequency of abnorma I pregnancy among group_s of · 
women identifted as they enter the s'tudy a't 20 weeks and require a large study 
popula.,.ion in order to detec"f" rare abnormalities. C3> case series observ~ a 
select group of abnormal pregnancies but without comparable information on 
normal women and without a denominator and (4) clinical trials 
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where, tn additton to eonfoundtng be"hi#een congeni~al detec~s and cases of 
Threatened abor~ion, the sample size is usually too smal I to detect uncommon 
ab norma I t t t es o 
Or .. Gray reviewed 't"he epidemiologie studies 't'ha"f> associate bir1"h defect's "'1i1"h 
proges.,.tn use and poin-ted out their shorteomings.11 i .. e. confounding., lack of 
accurate drug hf story, drug use, biased information gatherJng, and- accuracy of 
The levy s+udy of cardiovascular defects dtd not provide- information of the 
spec.ifte na+ure of s~erotds used or a careful analysts of the indications for 
drug usee Thts and other studies estimate an unproven risk associated with . 
) estrogen and progestln use In c:cmbinatfon of about 1.5 to 2 fold. 
The i net dence- ot. mascu I in i zati on of 1-he fema I e fetus ~ssod ated w I 'th 
in'f-rauterine exposure ~o steroids. whil~ difficult to ev~l~at&., is estimated 
i 
as abou't" 1%o v·ery high· doses ot proges1"ins -for sufficfent dura'tion may cause 
vi~f I iza"f>ion bu-t- i't" ts unclear if the risk of· hypospadias or o1"her 
' geni~o-urinary abnormalities is increasedo If they do, the risk ts likely to 
be exceedingly smal lo 
From several published reports it seems uni ikely that proge-stins signiticantly 
increase the risk of neural tube defectso 
} _, 
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In the case of I imb defects, the Janerich estimate o~ a relative risk of 4o2 
is difftcult to evalua-te due to recalJ bias anc inadeqa-t-e.control of 
confounding f~orsc The reported VACTERAL syndrome in the Nora report·canno~ 
be considered conclusive due to· a confused experimental design, recall bias, 
confounding, and arbitrary grouping. The Cooperative Perinatal Project did 
not observe an assocta•fon between limb reduction defects-and intrauterine. 
exposure "!-o proges1"lns., 
The·s+udy of non specific chromosomal abnormalities among induced abortions-or 
new born tntan~s exposed to oral eontracepTives producad·nonsignifican~c 
resul+s wi-thou1" evidence of an assocta+ton be1"ween hormonaf exposure and 
Down's Syndrome. 
White unproven, "fhe li1"eraTure suggests there may be a less than two-fold risk 
of cardiovascufar defec:Ts assocta-ted wi+h exposure to pr-ogestins• This.risk, 
however, is insufffc:ien1" to prohibit the use of a beneficial Therapy. Or. 
Gray cone: I uded tha-t -t-ne ep i demlolog i cal ·da1"a Is confused, I nc:onc I us ive and, ai" 
+he bes"f",, only suggestive. 
Anne Wen"f"z, M.Q., Oepar-tmen-t- of Obstetrics and Gynecology, Vanderbil"f 
Unfversii"y, reviewed ovarian fol ltcuJar developmenrt', corpus lu~eurn func-t-ion in 
early pregnancy, the ~iagnosis ~nd the role of progesterone Therapy for 
1"rea-tinent of lu1"eal phase def icfenc::y • 
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At about day 25, an increase in fol ltcle stimulating hormone CFSH> stimulates 
fol I lcle growth and emergence of a primary fol I icle accompanied by granulosa 
eel I hyperplasia, an Increase tn FSH and luteinizing hormone CLH> synthesis of 
LH ~nd FSH receptors and of the aromatase enzyme for conversion of androgens 
to estrogeno The increase in peripheral concen'tration of progesterone and 
es1'rogen s1"imulates +he pre ovula-tory LH surge preparing the follicle for 
progesterone synthesis and the re-initiation of oocyte maturationo Prior to 
ovula·Mon, a+ the mf·d and la1'e fol ltcular s1"a1"e, and during ~ubal transpori", 
the ovum is exposed 'i"o elevated proges1"erone concen-t-ratlon .. 
The primary func-+-i ons of progesterone and 17-0H progesterone are the 
establishment of a secretory endometrtum and to prevent rejection of 
trophobf astic tissueG Since the peripheral progesterone and 17-0H 
proges~erone levels decrease after ovulation and remain at lower levels unti I 
the produe'+' ion of p I acen-t'a I proges-terone 9 abet.rt day s i x-ty of pregnancy,, 
supplemen~ation of progesterone is needed before the m-issed menses and before 
pregnancy is first detectedo 
Firs~ identified by progesterone deficiency and later by endometrial biopsy, 
lu~ear phase defect occurs in 3-5$ of infertile women, anong anovulatory 
clomiphene ~reated pa.,,.ients~ wome~ in chronic a'fhletic training, and is 
associated with infertility and recurrent miscarriage. The concepT of luteal 
phase defect has recently been extended to an endometrial target tissue 
incapable of allowing ov~~ implantationo 
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Progesi-erone suppos l ~or- i es, Z5 mg twice da r' I y, star1-ed after an increase in 
basal body 1"empera1-ure and con1"inued un1"i J menses or in'i"o_ early pregnancy_ 
achieves-Jevels noi" in excess of those observed during the normal lu'teal phaseo 
In a- S'tudy of six hundred cases of primary infer1"i I ity, 'fhe_ IL.rl"eal phase 
defec't was ldentffled fn thir-f"yor;>three women as the sole cause- of infer·M I ity_ 
and trea'tment with progesterone resulted in a cumufa'tive -pregnancy rate of 50%0-.· 
Charles Hanmond, M.O .. , Oepartmen't of Obs-t-ei"r-fcs and Gyneco-logy, Duke- -
Un iversi'f"y Medi cal center, defined I u<f"ea I phase def I c i ency as- an- abnorma I i -ty. 
of 1-h.e corpus lu'teum si"eroid producing mechanism manifes-ted eJther by 
decreased proges~erone levels and/or brief luteal phase durcrf"::i.on, diagnosed- in 
several cycles by endometrial biopsy, serum progesi"erone_ -levels and basal body-
'tempera"f>ure changes. 
Wht Je ~here are no randomized con-trol s1'udies. luteal phase defects are 
treated- with 25 mg vaginal proges1'erone supposi+orfes tw-ice daily ·unt_i I either 
onse'f" of menses or diagnosis of pregnancy and continued un1"-i-I -the- I O-J 2'th· week 
of pregnancy. 
Successful pregnancies occurred with either OelaJutin supp:lemen""tation, 250-mg 
once per ·i11eek, or no "f"reaimen1". with no fe~a I anoma I i es observe<t i-n- -tr-ea"f"ed 
pa"t'f en~s .. 
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Or. Hannond believes luteal phase defect extsts anong some patients and 
treatment with 2S mg progesterone suppositories approached the physiologic 
concentrations observed during the luteal phase wiThout a teratogenic risk. 
Or. Reddick, M.D., University of Connecticut College of Medicine, reviewed his 
da-t-a on prolactin as a possible biochemical marker of progesterone produc"fion. 
Prolactin is synthesized .2!, ~ Tn pregnant, cycling, and non pregnan-t-
endome~ial -tissue from about day 24 of the mensiTual cycle and may be 
considered a biochemical marker for progesteronea In vitro prolacttn 
production ts increased by proges-t-erone but inhibited by estrogen, suggesting 
es'i"rogen as a possible cause of an endometrlal matura1"fon detect. 
) Luteal phase defect ts dfagnosed by endometrial btopsy in two c:ycies and 
trea•ed wi~h 25 mg proges-terone .suppositoFi~s twice daily e . There were no 
congenttal malformations anong eighteen of twenty~two treated pregnancies that 
nave de I i vered· w-i -th 5 spon'i'"aneous ear I y mi sc:arrf ages., Progesterone is noi" 
only fmpor+ant for his1"ologic: ma<f"urcrtion of 1-he endometrium but for the actual 
biochemical ae~tvi't"y of that tissueQ He believes identification of a hormonal 
deficiency +haT prevents implantation and early embryonic development 
necessi•a•es treating •hat deficiencyo 
The tera~ogenic effec~s of progesterone therapy in a large private practice 
was presented by Joseph Festep MoOG. Department of Obstetrics and Gynecology, 
Saylor Unive:si+y Cof lege of MedicineG 
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?r"ogP.~~erone 1T'Aa1inent consisted of vaginal suppositories three days a+~e".'. 
rlsP. In ba~at body tP.mpP.ratur-P. urrTif ~he 36i"h day sincP. thP. last menstrual 
period folfoWP.d by 17 hydroxy-progesterone until the 50-601"h day o+ 
pregnancy. The 1150 wcmen tr-~atP.d witn Oelalutin +or various !ndfcai"icns, _and __ 
2700 matche:td. con'h-ol patients, were o• comparable age, gr-avidity and partty, 
rt=tcPived '?5o-:;oo rng/triject!oo mos~ly weP.kty fO'· +r-om 1-20 weeks ol pt:"egnancy. 
The tnc:tdenc:e of cor.igenttal mul1"fvrtate anomal f P.45 was 14.7/1000 In treated 
an(')ma I t P~ wP.rP. ac;soc t atAd with h-ert d f sease t'hat cou Id poss lb t y bP. attr:- i buted 
J(')urna! Qbstetr-tcs and GynACotcgy 141:567, 1981>, Gr-ay and Shardein_ 
17-0H p,..ogestP.f'"'one for the tr'eatrm=tnt of r-epr-oductfvP dlsor-(J~s. 
~·ud f Pc; t nv() t VP a WP I I dP+ I nPd c I t n i ca I and endocr- i no I og I ca I patt ~n1" 
bP r-Aa~onable ~n conduc-t 'ur-thP.r ~tudf P!' wi~h po~iTivP contr-ols, to det...-mi11P 
t t~ ,.u i c acy • 
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The committee recommended labeling changeso The amended label should indicate 
thaT progesterone and 17-0H progesTerone do not appear to have any significant 
teratogentc potenttal and the current labeling, suggesting teratogenic 
po~enttal of sex hormones, be modifiede 
The recommended dose of progesterone for luteal phase deficiency should be 
ef-ther proges-ter·one in oi I 12 .. 5 mg daily in'framusc:ul arly or 25 mg 
suppos icfoor i es i'w ice da i ly, either vagina I ly or reci'a I ly o 
The eommi-H-ee does no~ curren~ly have enough data to documenT the absorption 
characteristics of tntravaginal progesterone To establish a dose leveio 
However, "a maximum dose of 200 mg daily for fourteen days should not be 
exceededQ Addi+ionai information fs needed +o determine the relationship 
be1-ween various doses of progesterone and resu!~tng serum levelso 
ATG/sn/12/25/81/32.558 
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ORAL CONTRACE?TtVE LABELING 
Llnyd MlllSTPfn, ?h.Do. Oepu~y.QirPCtor, Qtv!sion ~f Qrug Labeling reviewed 
the JunP. 1979 Food and Drug label Ing regulations and l""P.qulramP.rr!·so 
ThP. labPltng of drug product's choufd prP$Prr,_ accu,.ate, easy to r-ead. non 
promntfonal fnformatton that ts not mlsleadfng and is wfThout implied claims 
rye ~uggP.ct f on~ of d,...ug use whN"e there ts l nadequate ev I dence. o+ sa+ety anct. 
pffectlveness .. 
The marn sections ot '!"he label irig ar-e Indications, w_arnings, precaµtloos, 
advP-rse reactions and dosage which provide guidance for safe_ and intel I igent 
USP. o~ thP. p~oduct. 
T~P pcT'po~P.~ of th~ packagP. labP.ling are (1) to provide adequate informatlon 
for the safe and ef~ecttve use o+ the drug <2> to act as an educat!onat 
rnr.rum-tnt r-egar"dfng a specf!+tc drug an.d C3> to pr"'ovtdP. the __ fac"hlal basis and 
th~ ttmftatfons tor the promotion of drugs tn thP. medlcaLcommuni"!"y. 
ThP. l ntent o-f the rev I SPd t abe I f ng Is to de 1.ete somP. comp I ex, d 1 tt I c:u l t to 
read. r-epetlt!ous Jnformatfon. to Include new Information and to tar-get areas 
that requtrP. further rPvf Pw and discussion. 
The committee Is r-F.tquAsted to review and comment on the pr-oposed changes and 
prov f dP. the best poccs I b IP. I abP. I Ing +or th I~ I mportan~ gr-oup ot drugs. 
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The FDA tabeltng ,..~vision ?rograrn states that al I marketed product label Ing 
must mePt the •or-maT and content of the new ~Agulation ~Y November 1984, the 
or'al contracP.pttve labetlng ts due May 1st 1982 and has an effective date of 
To facJ I ttate r"'evtew. the cur'rent label tng was divided into sections and 
Card tac 
Cerebr'ovascutar 
Howard Ory, MoOo 
Wiil lam Andrews, ~oOQ 
Ralph O'Agosttno, ?hoOo 
Phil Cor"+man, MeOo 
Hetnz Bef"'end@S 1i M .. Oc 
SP-Zar' Aksel, MoOo 
Gordon Avery. Mo00@ PhoOo 
Wt I I tam AndFews, MoO. 
' . 
CT a I Contracept Ive E~ ~ tcacy 
Genera I: C hypertens ton, ga I I b I addef"', ectop le prP-gnancy, d I abetes) 
Ron Nelson~ M.Oe 
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Labora1"ory Tes1's 
Wllltam Easterling, MoO., 
The c:cmmlttee will review tne proposed changes. recen'tly·publisned-r'epor"fs, 
and dtscu~s these 11 in open session at a February meeting. 
I certify tha~ I ai"tended 1"he November 5,5, 1981 mee1"ing of the Fer--tiiii"y and 
· Ma-t-ernal Heal Th Drugs Advisory Committee and that 1-hese mirurtes adequata~y _ 
Feflec:t the proceedings. 
~ --1/ . 
. _ ~ . c '-'-~ r U..i .... tt. . .:.... ~'"'~-­
oav id Arch-er, M .0., 
Chairman 
ATG/em/1/4/Sl/31559 
"\ 
_..,,,,,. . 
· t~;.:./' r. ···~ z ._, I :-j. •. / 1 .J; 
A., T. Gregoire, --Pn;;-o ... _ 
l Executive Secretary 
oa-re 
.. 
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INSTRUCTION NO. if2.t_ 
. You can find the Delalutin in question to have been in 
a defective condition unreaaonably d~gerous _only if you deter-
mine that Squibb. failed to warn of a known danger in the use of 
. . . 
. 
the Delalutin, or a danger which should have· been known iiven the 
- . •"-• ·.· 
- . 
o •,.'.,4>1_-: :"' -~••• •O,.&.P • ....... 
state of· technological development at the time the drug was 
administered to lCathleen Barson in 1972 •. 
. -------------------·-·- ·-- ···- ···--- .. 
RESTATEMENT (SECOND) of TORTS §402A Commencs j_and k; 
Ernest W. Hahn Inc. vs. Armco Steel Co., 6.01 P2d 152. (Utah. 
19-79) • 
. . · ... 
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